A phase II trial of S-1 plus cisplatin with concurrent proton therapy for locally advanced NSCLC
Not Applicable
- Conditions
- unresectable stage III NSCLC
- Registration Number
- JPRN-UMIN000036978
- Lead Sponsor
- agoya City West Medical Center
- Brief Summary
The 2- and 5-year OS were 77% (95% confidence interval 64%-89%) and 59% (43%-76%) The median OS was not reached. No grade 3 or higher radiation pneumonitis was observed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 41
Inclusion Criteria
Not provided
Exclusion Criteria
(1)superior vena caval syndrome (2)Other cancers within 5 years (3)active and uncontrolled infection (4)Other serious complications (5)IP or IPF on X-p (6)pregnancy or lactation (7)portal vein tumor thrombosis (8)severe psychological disorders (9)malignant pleural effusion (10)uses fluoropyrimidine antineoplastic agent or flucytosine (11) cases in which the doctor is judged inappropriate for medical, psychological or other reasons other than the above (12)a coronary stent and aortic stent graft
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year overall survival
- Secondary Outcome Measures
Name Time Method acute and late toxicity,response rate, local control rate, median survival, progression free survival,change of quality of life (QOL)